DAP12 (KARAP) amplifies inflammation and increases mortality from endotoxemia and septic peritonitis by Turnbull, Isaiah R. et al.
T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
 
JEM © The Rockefeller University Press $8.00
Vol. 202, No. 3, August 1, 2005 363–369 www.jem.org/cgi/doi/10.1084/jem.20050986
 
BRIEF DEFINITIVE REPORT
 
363
 
DAP12 (KARAP) ampliﬁes inﬂammation 
and increases mortality from endotoxemia 
and septic peritonitis
 
Isaiah R. Turnbull,
 
1
 
 Jonathan E. McDunn,
 
2
 
 Toshiyuki Takai,
 
4,5
 
 
 
R. Reid Townsend,
 
3
 
 J. Perren Cobb,
 
2
 
 and Marco Colonna
 
1
 
1
 
Department of Pathology and Immunology, 
 
2
 
Cellular Injury and Adaptation Laboratory, Department of Surgery, 
and 
 
3
 
Department of Medicine and Proteomics Center, Washington University School of Medicine, St. Louis, MO 63110
 
4
 
Department of Experimental Immunology, Institute of Development, Aging and Cancer, Tohoku University, Seiryo 4-1, 
Aoba-ku, Sendai 980-8575, Japan
 
5
 
Core Research for Evolutional Science and Technology, Japan Science and Technology Agency, Honcho 4-1-8, Kawaguchi, 
Saitama 332-0012, Japan
 
DAP12 (KARAP) is a transmembrane signaling adaptor for a family of innate immunoreceptors 
that have been shown to activate granulocytes and monocytes/macrophages, amplifying 
production of inflammatory cytokines. Contrasting with these data, recent studies suggest 
that DAP12 signaling has an inhibitory role in the macrophage response to microbial 
products (Hamerman, J.A., N.K. Tchao, C.A. Lowell, and L.L. Lanier. 2005. 
 
Nat. Immunol.
 
 
6:579–586). To determine the in vivo role for DAP12 signaling in inflammation, we measured 
the response of wild-type (WT) and DAP12
 
 
 
/
 
 
 
 mice to septic shock. We show that DAP12
 
 
 
/
 
 
 
 
mice have improved survival from both endotoxemia and cecal ligation and puncture–
induced septic shock. As compared with WT mice, DAP12
 
 
 
/
 
 
 
 mice have decreased plasma 
cytokine levels and a decreased acute phase response during sepsis, but no defect in the 
recruitment of cells or bacterial control. In cells isolated after sepsis and stimulated ex vivo, 
DAP12 signaling augments lipopolysaccharide-mediated cytokine production. These data 
demonstrate that, during sepsis, DAP12 signaling augments the response to microbial 
products, amplifying inflammation and contributing to mortality.
 
DAP12 (KARAP) is a transmembrane signaling
adaptor associated with a family of activat-
ing immunoreceptors, including the KIRs,
Ly49s, NKG2C/E, TREMs, SIRP-
 
 
 
1, CD200R,
MDL-1, and others (1–4). These receptors are
expressed on the surface of NK cells and myeloid
cells, including macrophages, granulocytes, den-
dritic cells, osteoclasts, and microglia. DAP12
contains cytoplasmic immunoreceptor tyrosine-
based activation motifs (ITAMs; references 1–3).
Engagement of a DAP12-associated receptor
induces tyrosine phosphorylation of the ITAM
by Src kinases. The phosphorylated ITAM re-
cruits the protein tyrosine kinases Syk and
ZAP70, triggering phosphorylation of multi-
ple  downstream mediators, including PI-3K,
PLC-
 
 
 
, c-Cbl, Grb-2, and Vav, that ultimately
lead to cellular activation (1–3, 5).
We previously showed that antibody ligation
of the DAP12-associated receptor TREM-1
on granulocytes and monocytes induces release
of the inflammatory cytokines TNF-
 
 
 
 and IL-8
(6). In vivo, blockade of the DAP12-associated
receptor TREM-1 was associated with re-
duced inflammation and increased survival
from endotoxemia or septic peritonitis (7).
These observations suggest a role for DAP12
and at least one of its associated receptors in
the amplification of the inflammatory response
induced by pathogens and their components.
Consistent with this, DAP12 transgenic mice
exhibited increased systemic inflammation and
mortality during endotoxemia (8). Moreover,
overexpression of DAP12 increased hepatic
granulomatous inflammation elicited by zymo-
san A, whereas blockade of TREM-1 reduced
granuloma formation (9).
In contrast to the established role for
DAP12 in activating inflammatory responses,
experiments with DAP12-deficient macrophages
found no defect in TNF-
 
 
 
 or nitric oxide pro-
duction after ex vivo stimulation of peritoneal
macrophages with LPS, suggesting that these
cells have no intrinsic defect in the response to
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microbial products (10). Moreover, Hamerman et al. (11)
have recently reported that macrophages derived from
DAP12-deficient mice have an increased response to low
concentrations of microbial products and that DAP12
 
 
 
/
 
 
 
mice are more sensitive to LPS after pretreatment with the
TNF-
 
 
 
–sensitizing reagent 
 
D
 
-galactosamine than are WT
mice. Collectively, these results suggest an inhibitory role for
DAP12 in regulating the inflammatory response and conflict
with the described role of DAP12 in activating myeloid cells
and previous data implicating the DAP12-associated receptor
TREM-1 in exacerbating inflammation, endotoxemia, and
septic shock.
To address this conflict, we sought to understand the
function of DAP12 in physiologically relevant models of in-
flammation. To this end, we measured the contribution of
DAP12 to septic shock induced by endotoxemia and cecal
ligation and puncture (CLP).
 
RESULTS AND DISCUSSION
DAP12 signaling contributes to inflammation and mortality 
from endotoxemia
 
To determine if DAP12 contributed to the in vivo response
to endotoxin, we subjected WT and DAP12
 
 
 
/
 
 
 
 mice to i.p.
injections of LPS and monitored them for survival. DAP12-
deficient mice tolerated doses of 5 and 6.25 mg/kg of endo-
toxin, which resulted in 60–100% mortality in WT mice
(Fig. 1 A). However, DAP12-deficient mice were not com-
pletely refractory to endotoxin and died at a dose of 10 mg/
kg (Fig. 1 A). Thus, DAP12 signaling contributes to endo-
toxemia, although it is not required for the response to LPS.
Endotoxin causes shock by inducing macrophage pro-
duction of TNF-
 
 
 
 and other proinflammatory cytokines
(12). To determine if DAP12 signaling exacerbated endo-
toxemia by increasing cytokine production, we measured
cytokine levels in mice treated with 5 mg/kg of endotoxin.
It has been shown that inflammatory cytokine levels peak af-
ter 1–3 h of endotoxemia infection (12). We found that 2 h
after injection of LPS, both WT and DAP12
 
 
 
/
 
 
 
 mice had
elevated circulating levels of TNF-
 
 
 
, IL-6, MCP-1, and IL-
10. When compared with DAP12
 
 
 
/
 
 
 
 mice, WT animals had
significantly higher levels of TNF-
 
 
 
 and IL-10. By 4 h,
TNF-
 
 
 
 and IL-10 were reduced in WT mice, and the levels
were equal to the DAP12
 
 
 
/
 
 
 
 animals (P 
 
 
 
 0.05; Fig. 1 B).
We conclude that DAP12 signaling can augment inflamma-
tory cytokine production acutely.
 
Mortality and inflammation from septic peritonitis is 
augmented by DAP12
 
Although mortality from endotoxin is mediated by inflam-
mation and overproduction of cytokines, surviving authentic
sepsis requires attenuating the inflammatory response, as well
as achieving bacterial control (13). To determine the role of
DAP12 in survival of sepsis, we subjected WT and DAP12-
deficient mice to CLP, a clinically relevant model of bacte-
rial peritonitis. We found that DAP12
 
 
 
/
 
 
 
 mice were highly
resistant to CLP (WT, 
 
n 
 
  
 
20, 0% survival; DAP12
 
 
 
/
 
 
 
, 
 
n 
 
 
 
19, 60% survival; Fig. 2 A).
Sepsis is associated with high circulating cytokine levels
that contribute to shock (13). To determine if DAP12 con-
tributed to cytokine production during sepsis, we measured
cytokine levels in the plasma of WT and DAP12-deficient
mice 6 and 24 h after CLP. At 6 h, WT and DAP12
 
 
 
/
 
 
 
mice had measurable plasma levels of IL-6, MCP-1, and
TNF-
 
 
 
, but there was no difference between the two
groups. Between 6 and 24 h, WT plasma cytokine levels had
increased dramatically such that by 24 h after the onset of
sepsis, the WT mice had significantly higher levels of IL-6,
MCP-1, TNF-
 
 
 
, and IL-10 than did DAP12
 
 
 
/
 
 
 
 mice (P 
 
 
Figure 1. DAP12 signaling augments mortality and inflammatory 
cytokine levels during endotoxemia. (A) Survival of WT and DAP12 /  
mice after endotoxemia was measured at three different doses: 5, 6.25, 
and 10 mg/kg (n   5 for all doses). At both 5 and 6.25 mg/kg, DAP12 /  
mice had improved survival as compared with WT mice (P   0.05 by the 
log-rank test). At 10 mg/kg, both strains died. (B) Plasma was harvested 
from WT and DAP12 /  mice 2 (n   5–6), 4 (n   3), or 24 (n   3) h after 
injection of 5 mg/kg LPS. At 2 h, WT mice had increased levels of TNF-  
and IL-10 (*, P   0.05 vs. WT by the Mann-Whitney test). 
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0.05; Fig. 2 B). These data demonstrate that DAP12 signal-
ing contributes to cytokine production during sepsis.
To determine if there were other DAP12-regulated fac-
tors mediating the increased sepsis mortality of WT mice as
compared with DAP12
 
 
 
/
 
 
 
 animals, we examined plasma
proteins from these mice using two-dimensional difference
gel electrophoresis (14). Plasma was isolated from WT and
DAP12
 
 
 
/
 
 
 
 mice 24 h after CLP, and plasma proteins were
resolved by isoelectric point and size. Relative abundance of
the individual gel features was compared between the two
genotypes, and features that were substantially different in
four independent experiments were isolated and identified
by mass spectrometry. We identified seven differentially reg-
ulated proteins in 13 gel features (some proteins are repre-
sented by multiple gel features). Data are expressed as the
fold change in average florescence of DAP12
 
 
 
/
 
 
 
 versus WT
(Table I). The proteins identified in this unbiased approach
were previously described as acute phase reactants (15–20).
Positive acute phase proteins (proteins known to increase in
response to inflammation, i.e., apolipoprotein A-IV [15],
hemopexin [16], and complement component 3 [16]) ac-
counted for three out of seven identified proteins. Negative
acute phase proteins (those known to decrease with inflam-
mation) accounted for four out of seven proteins: major uri-
nary protein (17), antithrombin III (18), gelsolin (19), and
MHC Q10 (20). For every individual protein, the acute
phase response was attenuated in DAP12
 
 
 
/
 
 
 
 mice. This was
manifest as lower levels of positive acute phase proteins and
higher levels of negative acute phase proteins. Collectively,
these data show reduced plasma cytokine levels and a re-
duced acute phase response in DAP12
 
 
 
/
 
 
 
 mice, demonstrat-
ing a role for DAP12 in triggering inflammation.
 
DAP12 is not required for recruitment of cells 
or bacterial killing
 
We hypothesized that the absence of DAP12 could also re-
sult in a decreased cellular response to peritonitis. To address
this question, we measured the number and type of cells re-
cruited to the peritoneum during sepsis. We found equal
numbers of cells in the peritoneum of WT and DAP12
 
 
 
/
 
 
 
mice 24 h after the onset of sepsis (Fig. 3 A). By analyzing
surface markers on these cells, we found that in both WT
and DAP12
 
 
 
/
 
 
 
 mice, 50–60% of the cells were macrophages
(defined as CD11b
 
 
 
GR1
 
lo
 
) and 30–40% were granulocytes
(defined as CD11b
 
 
 
GR1
 
hi
 
; Fig. 3 C). The absence of
DAP12 does not appear to alter the recruitment of cells to
the peritoneum during sepsis. We also asked if there was a
deficit in bacterial control in the absence of DAP12 signal-
ing. To determine if DAP12 mediates bacterial control, we
measured bacterial load in the peritoneum at 24 h. We
found no remarkable difference in peritoneal infection be-
tween WT and DAP12
 
 
 
/
 
 
 
 mice (Fig. 3 B), demonstrating
that DAP12 is not required to control the peritoneal infec-
tion during sepsis.
Figure 2. DAP12 signaling augments mortality and inflammatory 
cytokine levels during bacterial sepsis. WT and DAP12 /  mice were 
subjected to CLP, and survival (A) and cytokine production (B) were assessed. 
DAP12 /  mice (n   19) are resistant to CLP as compared with WT mice 
(n   20; P   0.001 by the log-rank test). Plasma was harvested from WT 
or DAP12 /  mice before CLP (n   5) and either 6 (n   6) or 24 (n   12–15) h 
after CLP, and cytokine levels were measured. At 6 h, we found elevated 
but equal levels of MCP-1, IL-6, and TNF-  in WT and DAP12 /  mice. By 
24 h, WT mice had significantly higher levels of MCP-1, IL-6, TNF- , and 
IL-10 (P   0.05 by the Mann-Whitney test). Values shown are SEM.
 
Table I.
 
 . Differential plasma proteins induced by sepsis in 
DAP12
 
 
 
/
 
 
 
 versus WT mice
 
Differentially represented
plasma proteins Fold change p-value
 
Positive acute phase reactants
Apolipoprotein A-IV
 
 
 
1.56 0.05
Hemopexin
 
 
 
3.68 0.024
Complement component 3
 
 
 
3.17 0.0005
Negative acute phase reactants
Antithrombin 1.69 0.0047
Gelsolin 1.72 0.0018
Major urinary protein 3.49 0.006
MHC Q10 
 
 
 
 chain 2.13 0.04
 
Proteomic analysis of plasma from DAP12
 
 
 
/
 
 
 
 and WT mice 24 h after CLP identified 
seven differentially regulated proteins. Identified proteins were previously described 
as acute phase reactants (15–20), demonstrating a role for DAP12 in inducing the 
acute phase response during sepsis. Mean fluorescence intensity was compared using 
the Student’s 
 
t
 
 test. Data are expressed as the fold change of DAP12
 
 
 
/
 
 
 
 versus WT. 
DAP12 INCREASES INFLAMMATION FROM SEPSIS | Turnbull et al.
 
366
 
DAP12 signaling augments in vitro cytokine production of 
peritoneal macrophages obtained from septic mice
 
Although our observations indicate that in vivo DAP12 sig-
naling augments cytokine production, previously published
data demonstrated that there is no defect in ex vivo macro-
phage activation in the absence of DAP12 (10). To address
this apparent discrepancy, we measured cytokine production
by peritoneal exudate cells induced by sepsis. Peritoneal cells
were isolated by peritoneal lavage and tested for their ability to
produce cytokines ex vivo either without or with LPS stimu-
lation. We found that cells isolated from the peritoneum of
both WT and DAP12
 
 
 
/
 
 
 
 mice after CLP produced cytokines
in the absence of any additional stimulation (Fig. 4 A). How-
ever, cells isolated from WT mice produced more MCP-1,
TNF-
 
 
 
, and IL-10 as compared with cells isolated from
DAP12
 
 /  mice. Although the cells are cultured in the pres-
ence of antibiotics, we cannot determine if this cytokine se-
cretion reflects stimulation by bacterial products carried over
from the frankly septic peritoneal lavage fluid or if this cyto-
kine production reflects activation induced by previous stimu-
lation in vivo. To normalize the stimulation via Toll-like re-
ceptors (TLRs) and to exclude the possibility of differential
carryover of microbial products, we treated the cells with 1
 g/ml LPS, which resulted in maximal stimulation and in-
creased cytokine production by WT and DAP12 /  cells.
Under these conditions, we found that WT cells were al-
ways considerably more efficient at cytokine production than
DAP12 /  cells (Fig. 4 A). Remarkably, when we examined
ex vivo cytokine production by thioglycollate-elicited perito-
neal exudate cells from WT and DAP12 /  mice, we found
no statistically significant differences in IL-10, IL-6, MCP-1,
or TNF-  (Fig. 4 B), whereas there was a trend toward an in-
crease in IL-10 production by DAP12 /  cells. We conclude
that DAP12 signaling augments cytokine production only in
macrophages stimulated in vivo by septic peritonitis.
Concluding remarks
Our data show that DAP12 augments the inflammatory re-
sponse induced by endotoxemia or authentic sepsis by four
measures: increasing circulating cytokine levels, increasing
the acute phase response, augmenting cellular inflammatory
cytokine production, and, ultimately, increasing mortality.
Figure 3. DAP12 signaling does not contribute to cellular recruit-
ment or bactericidal activity. 24 h after CLP, peritoneal exudate was 
harvested by peritoneal lavage. Total cell numbers (A; n   16–17), bacterial 
load (B; n   11–12), and distribution of cell types (C; n   4–5) were measured. 
We found no difference between WT and DAP12 /  mice. Each asterisk 
represents a measurement for a single mouse.
Figure 4. DAP12 signaling augments ex vivo cytokine production 
by macrophages after sepsis but not sterile peritonitis. WT and 
DAP12 /  mice were subjected to CLP, and peritoneal cells were harvested 
after 24 h (n   8–12). (A) Cells were cultured ex vivo with or without 
stimulation with 1  g/ml LPS, and levels of cytokine in the supernatant 
were measured. With no stimulation, WT cells (black bars) produced more 
IL-6, MCP-1, TNF- , and IL-10 as compared with DAP12 /  cells (hatched 
bars; *, P   0.05; **, P   0.01 by the Mann-Whitney test). After LPS stim-
ulation, WT cells produced increased amounts of TNF- , MCP-1, and IL-10. 
(B) Cells were also harvested 72 h after i.p. injection of thioglycollate broth 
and cultured ex vivo with (10, 100, or 1,000 ng/ml) or without LPS (n   3 
for all cultures). There was no statistically significant difference between 
WT and DAP12 /  cells, although there was a trend toward increased IL-10 
by the DAP12 /  cells with maximal stimulation. Values shown are SEM.JEM VOL. 202, August 1, 2005 367
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These data are consistent with the previously described role
for the DAP12-associated receptor TREM-1 in septic shock
(7) and support a physiologic function of DAP12 in activat-
ing granulocytes and/or macrophages.
Hamerman et al. (11) have recently shown that bone
marrow–derived macrophages derived from DAP12-defi-
cient mice are hyperresponsive to TLR ligands and pro-
duce increased amounts of TNF-  in response to low levels
of TLR stimulation. Moreover, these authors show that
DAP12-deficient mice are more susceptible than WT ani-
mals to endotoxin after the mice have been treated with the
TNF-  sensitizing agent galactosamine (11). D-galactos-
amine treatment sensitizes mice to TNF-  by blocking he-
patic protein synthesis, and galactosamine-induced mortality
can be prevented by strategies that neutralize TNF-  (21).
These data suggest that DAP12 inhibits activation of macro-
phages and/or granulocytes, at least in the presence of low
levels of TLR stimulation. However, the relevance of this
model to clinical sepsis (or the physiologic response to bacte-
rial infection) is unclear because the mortality in this model
occurs within 12 h. This contrasts with the models of septic
shock that we use (simple endotoxemia and CLP), which
more adequately recapitulate the clinical situation where
mortality occurs over multiple days.
The discrepancy between our results and those of Ha-
merman et al. may be explained by the differential patho-
genesis of the two models. Mortality by endotoxemia after
D-galactosamine treatment is mediated by TNF-  (21), and
death occurs within 12 h of injection with LPS. TNF-  also
contributes mortality from simple endotoxemia, but other
factors, including IL-1 (22), HMGB-1 (23), and MIF (24),
participate in endotoxemic death; moreover, death after sim-
ple endotoxemia occurs over 3–5 d (13). Therefore, it is
possible that high concentrations of LPS, elevated inflamma-
tory cytokines, and an extended time course of inflammation
in simple endotoxemia may induce the expression of high
affinity DAP12-associated receptor–ligand pairs that can syn-
ergize with TLR-mediated pathways to drive cytokine pro-
duction as described for ligation of TREM-1 on macro-
phages or granulocytes (6). Consistent with this hypothesis,
we have previously shown that microbial products induce
expression of TREM-1 (6). In the D-galactosamine model,
the low levels of LPS and the reduced time course of disease
may induce only low affinity DAP12-associated receptor–
ligand interactions. As a result, DAP12 may preferentially re-
cruit inhibitory mediators, including c-Cbl, or other unde-
scribed mediators, leading to an alternative signaling pathway
analogous to that induced by ligation of FcR  (25). This al-
ternative activation could modulate or antagonize TLR-
mediated signaling.
These differential roles of DAP12 signaling may allow for
“fine tuning” of the cellular response to infection in vivo. The
range of endotoxin levels tested by Hamerman et al. ex vivo
correlates with circulating plasma LPS levels in both mouse
(26) and human sepsis (27). In contrast, LPS levels at the site
of infection can be dramatically higher. For example, perito-
neal LPS levels after CLP can range to 20 ng/ml (26), past the
range for an inhibitory function of DAP12. Thus, even
though low LPS concentrations distal to the site of infection
may prevent unnecessary DAP12-mediated inflammation, at
the nidus of infection, in the presence of high concentrations
of LPS, DAP12 may become completely activated and syner-
gize the TLR to mediate cytokine production.
MATERIALS AND METHODS
Mice
DAP12 /  mice (28) were backcrossed onto the C57BL/6 background.
The genetic background was analyzed by simple sequence length polymor-
phism typing, and the colony was expanded after  99% of the genome was
derived from the C57BL/6 strain. WT C57BL/6 controls were purchased
from Taconic Labs. All studies were approved by the Washington Univer-
sity School of Medicine Animal Studies Committee.
CLP and endotoxemia
Sepsis was induced by CLP. Mice were anesthetized with 2.5% halothane,
and the cecum was exteriorized through an abdominal incision. The cecum
was ligated distal to the ileocecal valve and punctured twice with a 25-
gauge needle. The cecum was replaced, the abdomen was closed with 4–0
silk sutures, and the mice were given 1.0 ml of normal saline s.c. for volume
resuscitation. Endotoxemia was induced by i.p. injection of LPS (Salmonella
abortus equi; Sigma-Aldrich), dissolved in 0.2 ml PBS, at the dose indicated
in the figures.
Peritoneal cell isolation and characterization
Peritoneal cells were isolated by peritoneal lavage with 3   5 ml PBS. Cells
were washed twice with 10 ml of normal saline and were resuspended in
RPMI 1640 with 10% FCS, 2 mM glutamine, 100  g/ml kanamycin, 1
mM Na-pyruvate, and 100  g/ml of nonessential amino acids. Sterile peri-
tonitis was induced by i.p. injecting 1.5 ml of thioglycollate media, and cells
were harvested 72 h after the insult. To determine the total number of peri-
toneal cells, peritoneal fluid was diluted 1:10 in 3% acetic acid to lyse eryth-
rocytes, and nucleated cells were enumerated on a hemocytometer. Cell
differential in the peritoneal fluid was determined by flow cytometry. Peri-
toneal cells were stained with anti-CD11b–FITC (BD Biosciences) and
anti-GR1–PE (BD Biosciences) for 20 min on ice. Cells were washed twice
and acquired on a flow cytometer (FACSCalibur; BD Biosciences. Macro-
phages were defined as CD11b /GR1lo; granulocytes were defined as
CD11b /GR1hi. For ex vivo cytokine production, peritoneal cells were
isolated by peritoneal lavage and cultured overnight in the presence of LPS
at the concentrations indicated in the figures. To determine bacterial load in
the peritoneal fluid, 100  l of peritoneal fluid was serially diluted 1:10 in
sterile PBS and was plated on sheep’s blood agar plates. Colonies were
counted after overnight incubation at 37 C.
Cytokine determination
Cytokines were measured using a cytometric bead array Mouse Inflamma-
tion Kit (552364; BD Biosciences) according to the manufacturer’s recom-
mendations. Samples were acquired on a flow cytometer.
Proteomic analysis of plasma
Sample preparation. Immunoglobulins were removed using protein A af-
finity chromatography (ProSep A; Millipore), and the resultant material was
desalted by gel filtration chromatography. Protein concentrations were deter-
mined using a modified Lowry method (PlusOne 2-D Quant; GE Health-
care). A pooled internal standard was prepared, comprising equal amounts of
each of the 10 experimental samples. Protein samples were labeled with
charge-matched cyanine dyes (GE Healthcare) as previously described (14).
Equal protein loading of WT plasma, DAP12 /  plasma, and the 10-sample
pool was based on protein assay results. Each of the five pairs of WT and
DAP12 /  samples were combined with 50  l of the pooled internal stan-DAP12 INCREASES INFLAMMATION FROM SEPSIS | Turnbull et al. 368
dard and were diluted by the addition of 300  l of rehydration buffer (7 M
urea/2 M thiourea, 4% CHAPS, and 0.5% vol/vol ampholytes, pH 3–10).
Two-dimensional gel electrophoresis and imaging. Labeled pro-
teins were separated in two dimensions. In brief, each combined sample
(450  l final volume) was rehydrated into a 24- cm, 3–10 nonlinear immo-
bilized pH gradient (IPG) strip (GE Healthcare), using a three-step voltage
protocol: 500 V, held for 500 V hours (Vh); 1,000 V, held for 1,000 Vh;
and 8,000 V, held for 64,000 Vh. After focusing, proteins were reduced and
alkylated by placing the IPG strips in 10 ml of equilibration buffer (50 mM
Tris, pH 8.8, 6 M urea, 30% glycerol, 2% SDS, and bromphenol blue) con-
taining 50 mg of freshly prepared dithiothreitol for 15 min at room temper-
ature, followed by adding 600 mg iodoacetamide in 10 ml of equilibration
buffer. IPG strips were then rinsed with 1  SDS running buffer (25 mM
Tris, 192 mM glycine, and 0.1% SDS) and layered on 10% polyacrylamide
gels and sealed with agarose (1% wt/vol in 1  running buffer). Second-
dimension SDS-PAGE separation was performed on all five gels simulta-
neously using 5 W/gel for the first 15 min, followed by 1 W/gel for 17 h
with circulating buffer (20 C) in the lower buffer chamber. The labeled-
pool, WT, and DAP12 /  proteins in each gel were individually imaged
using specific excitation/emission wavelengths for each dye (Cy2, 488/520;
Cy3, 520/580; Cy5, 620/670) using an imager (Typhoon; GE Healthcare).
Gel image analysis. The DeCyder Differential In-gel Analysis software
module (GE Healthcare) was used for “within-gel” image analysis for all sham/
CLP samples as previously described (29). The DeCyder Biological Variation
Analysis (BVA) module was then used to match all 15 protein-spot maps from
the five gels using the Cy2 (pool) image. Those gel features matched by the
software were manually inspected for accuracy and corrected. Images of plasma
from replicate samples were grouped within BVA, and differentially expressed
proteins were defined as those gel features with a value of P   0.05 using an
unpaired student’s t test for the comparison of WT with DAP12 / .
Gel feature processing.  Gel features were selected for excision in the De-
Cyder software. The 1.8-mm central cores of the selected gel features were ex-
cised robotically (ProPic; Genomic Solutions) and transferred to a 96-well
source plate. The gel pieces were digested in situ with trypsin (Promega) as
previously described (30). A 0.5- l aliquot of each digest was removed and
mixed with a matrix solution of 0.5  l  -cyano-hydroxycinnamic acid (Pre-
mix; Agilent Technologies). The mixture was spotted on a stainless steel target
for matrix-assisted laser desorption ionization (MALDI) mass spectrometry.
Protein identification by mass spectrometry.  Spectra of the peptide
pools were obtained on a MALDI-TOF/TOF instrument (ABI4700; Ap-
plied Biosystems). MALDI mass spectra ( 100) were acquired for each di-
gest and internally calibrated using trypsin autolysis peaks, and the top seven
most abundant signals (within m/z 900–2,000) were automatically selected
for tandem analysis. Precursor masses corresponding to a list of contaminant
masses commonly observed in this laboratory were excluded from the list of
precursor masses for tandem analysis. The peptide fragmentation spectra
were processed using Data Explorer (version 4.5; Applied Biosystems). Af-
ter centroiding and background subtraction, the spectra were used to search
the National Center for Biotechnology Information nonredundant database
using MASCOT (version 1.9; Matrix Sciences).
Statistical analysis
Statistical analysis was performed with GraphPad Prism software (GraphPad).
All cytokine determinations were compared by the nonparametric Mann-
Whitney test. All survival curves were compared by the log-rank test.
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